slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 33,541-33,570
Pages 10,126
Rows per page 30
Component
33,541-33,570 of 303,780
97
The diagram uses a process flow structure to show how various data sources are transformed into usable business assets.LSE | Investor Day Presentation Deck | 100 slides · LSEG
Conference presentation Investor relations 2 hits
04
The slide uses a two-column layout to present six key investment pillars.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 2 hits
05
The slide uses a split-layout comparing the company's mission/context on the left with the specific product value proposition and market statistics on the right.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations Beat · Problem2 hits
07
The slide uses a series of circular metrics to quantify the total addressable market and the urgency of the problem.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations Beat · Agitate2 hits
08
Includes a comparison to Exact Sciences' ColoGuard as a market positioning anchor.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations Beat · Solution2 hits
09
The slide uses a combination of bulleted arguments and a process-oriented visual flow to justify the economic value proposition.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction2 hits
10
Includes logos of four partner organizations.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations Beat · ActionLoop · Quick Win Big Bet2 hits
11
The slide uses a bulleted list to detail the partnership strategy, focusing on leveraging existing lab infrastructure to minimize marketing overhead.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations Beat · ActionLoop · Quick Win Big Bet2 hits
12
Includes a map of the US and Europe with color-coded status indicators.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations Beat · ActionLoop · Quick Win Big Bet2 hits
14
Includes a disclaimer at the bottom and a product visualization.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 2 hits
16
The slide lists four key executives: CEO, CFO, COO, and CSO.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 2 hits
17
Mainz Biomed NV | Investor Presentation Deck | 23 slidesMainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 2 hits
18
Mainz Biomed NV | Investor Presentation Deck | 23 slidesMainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 2 hits
20
The slide serves as a repository for additional information, specifically partner logos and team representation.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 2 hits
22
Mainz Biomed NV | Investor Presentation Deck | 23 slidesMainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 2 hits
01
Features a molecular structure visualization.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 2 hits
08
The chart uses a Gantt-style visualization to show progress from discovery through IND enabling phases.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 2 hits
09
Includes a section on 'Prior FDA Approval Experience' with company logos.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 2 hits
10
The slide features a 3D molecular rendering showing the inhibitor (pink) bound to the target protein (blue).Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 2 hits
11
The slide uses a three-part process flow to explain the biological mechanism of ROS1-driven disease and resistance.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 2 hits
12
The table highlights the clinical limitations of current standard-of-care drugs (Crizotinib, Entrectinib) due to resistance mutations like G2032R and CNS involvement.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank Beat · Market Sizing2 hits
13
The table uses a green/white color coding to highlight the competitive advantage of NVL-520.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank Beat · Market Sizing2 hits
15
The slide uses a structured table-like layout to define the product profile.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 2 hits
18
The chart uses a logarithmic scale to show relative selectivity ratios.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 2 hits
20
The slide highlights CNS activity via brain penetration, a key component of the NVL-520 target product profile.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 2 hits
21
The slide uses bioluminescence imaging to show tumor reduction and a Kaplan-Meier survival curve to show efficacy.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 2 hits
23
The slide uses a hybrid layout combining a staircase diagram for Phase 1 and a structured table for Phase 2.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank Loop · Quick Win Big Bet2 hits
24
The slide uses a high-quality 3D molecular rendering to illustrate the mechanism of action.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 2 hits
25
The slide uses a three-column process flow to explain the biological mechanism of ALK-driven cancer and resistance.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 2 hits
26
The slide highlights the clinical unmet need as patients progress through lines of therapy, specifically noting resistance mutations and CNS involvement.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank Loop · Cost Of Inaction2 hits